Ipilimumab and Local Radiation for Selected Solid Tumors

Inclusion Criteria: * Willing and able to give written informed consent * Before any study procedures are performed, subjects (or their legally acceptable representatives) will have the details of the study described to them, and they will be given a written informed consent document to read; then, if subjects consent to participate in the study, they will indicate that consent by signing and dating the informed consent document in the presence of study personnel * Histologically confirmed malignancy * In Phase 1, histologically confirmed melanoma. * In Phase 2, histologically confirmed melanoma, non-Hodgkin lymphoma, or colorectal carcinoma * Must have failed at least 1 systemic therapy or be intolerant to at least one prior systemic treatment * Must have at least 2 lesions of evaluable size by modified World Health Organization (mWHO)/Cheson criteria; 1 of 2 lesions must be amenable to biopsy (core or fine needle aspirate) and intratumoral injection of up to 5 mL (diameter ≥ 10mm) * Subjects with asymptomatic brain metastases are eligible; (systemic steroids should be avoided if possible, or the subject should be stable on the lowest clinically effective dose, as steroids as they may interfere with the activity of ipilimumab if administered at the time of the first ipilimumab dose) * Must be at least 28 days since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, or immunotherapy, and recovered from any …